Cryptogenic strokes can make patients feel adrift without answers

LINQTM family of ICMs will show you the way forward. Our NICE-recommended ICM solution can bring clarity and peace of mind.1

Learn how

Every 5 minutes someone in the UK has a stroke2

 

1.3 Million

stroke survivors in the UK2



 

25%

of ischemic stroke survivors remain cryptogenic, despite a comprehensive diagnostic workup3

Up to 30%

of patients with cryptogenic stroke may have previously undetected paroxysmal AF.4

Cryptogenic stroke is a challenge. Atrial fibrillation detection and treatment matter.

UK - stroke

The path away from secondary strokes can be plain sailing

The new ESO guidelines recommend, to maximize AF detection, clinicians should monitor cryptogenic stroke/TIA patients with  implantable cardiac monitors, starting as soon as possible.5

Let LINQTM family of ICMs illuminate your way

The Economic Model Used by NICE DG41 estimates that the number of strokes that could be avoided by using an ICM is 52 per 1,000 people with cryptogenic stroke.1

UK stroke

NICE Shared learning examples

Case study:
Salford Royal NHS Foundation Trust

Salford Royal NHS Foundation Trust added the use of an implantable cardiac monitor in people following cryptogenic stroke to their post-stroke aftercare pathways to help increase the detection of Atrial fibrillation (AF). This is in line with the NICE diagnostics guidance; Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke DG41.

Case study:
Cambridge University Hospitals NHS Foundation Trust

Cambridge University Hospitals NHS Foundation Trust have increased capacity to insert implantable cardiac monitors to detect atrial fibrillation after cryptogenic ischaemic stroke by using the joint stroke / cardiology multidisciplinary team, which is working to identify suitable patients.

Meet David

Meet david - UK stroke

David is 55 years old and a senior manager at an IT company.  David had a stroke last year, but the cause couldn’t be identified despite in-hospital investigations, including an electrocardiogram (ECG), 24-hour ambulatory monitor and echocardiogram.

A diagnosis of cryptogenic stroke was made and he was discharged on antiplatelet therapy, blood pressure medication and statins.  

Two months ago, he had a devastating second stroke… Scroll down and read the two downloadable documents to learn more about David’s journey and learn how leading clinicians approach cryptogenic stroke cases.

Icon, support imagery, Cryptogenic strokes can make patients feel adrift without answers

Guides to navigating Cryptogenic strokes

A practical guide to setting up an ICM service

Improving detection of atrial fibrillation after cryptogenic stroke with Implantable Cardiac Monitors (ICMs)

The case for change

Improving outcomes after cryptogenic stroke:
Why we need to address the patient pathway

If you plan to apply for a commissioned service and need support with the business case and dynamic healthcare economic model, please get in touch!

The role of prolonged cardiac monitoring in secondary stroke reduction

This meta-analysis6 found that patients who underwent  prolonged cardiac rhythm monitoring (PCM) compared to conventional cardiac monitoring showed: 

  • 2.5x increased incidence of AF detection
  • 2.1x increased incidence of anticoagulation initiation 
  • 55% decreased risk of recurrent stroke

Meet Jeanette - Real Life Patient Story

Jeanette was 57 years old when she suffered a stroke.

Listen to Jeanette’s story to hear how she felt about having Reveal LINQ™ inserted and how it improved her life.

Connect with an expert

*Indicates Required Field

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

References

1

NICE Diagnostics Guidance 41: Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke. September 2020 © NICE 2020. View full guidance.

3

Saver, JL. Cryptogenic Stroke. N Engl J Med 2016;374:2065-74. 

4

Sanna T, et al. N Engl J Med. 2014;370:2478-2486

5

Rubiera M, Aires A, Antonenko K, et al. European Stroke Organisation (ESO) guideline on screening for subclinical atrial fibrillation after stroke or transient ischaemic attack of undetermined origin. European Stroke Journal. May 2022. doi:10.1177/23969873221099478

6

Tsivgoulis G, et al. Prolonged Cardiac Rhythm Monitoring and Secondary Stroke Prevention in Patients With Cryptogenic Cerebral Ischemia. Stroke. Published online June 20, 2019. doi: https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.025169 

7

ICM Published Accuracy Comparison Guide. 2021.

Brief statement

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan™ device, see the MRI SureScan™ technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

 

For applicable products, consult instructions for use on www.medtronic.com/manuals. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

Important Reminder: This information is intended only for users in markets where Medtronic products and therapies are approved or available for use as indicated within the respective product manuals. Content on specific Medtronic products and therapies is not intended for users in markets that do not have authorization for use.